^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MSI (Microsatellite instability)

    i
    Other names: MSI | Microsatellite instability
    2d
    Comprehensive Genomic and Immune Profiling for the Detection of Clinically Significant Tumor Biomarkers (AMP 2024)
    Utilization of a multi-modal CGIP testing strategy resulted in a high rate of test success and detection of clinically relevant biomarkers and optimizing tissue usage.
    Clinical • Tumor mutational burden • IO Companion diagnostic • PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    PD-L1 expression • TMB-H
    |
    TruSight Oncology 500 Assay • Oncomine™ Immune Response Research Assay
    2d
    Automation of the Illumina TruSight Oncology 500 ctDNA v2 Assay on the Hamilton Microlab NGS STAR MOA System (AMP 2024)
    The TSO500 ctDNA v2 assay with automated library prep on the NGS STAR MOA liquid handler has demonstrated performance comparable to manual library prep and offers a high-throughput solution to enable comprehensive genomic profiling with a faster chemistry, more flexible workflow, and easier-to-use reagent kit.
    Next-generation sequencing • Tumor mutational burden • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TruSight Oncology 500 Assay • TruSight Oncology 500 ctDNA v2
    2d
    Comparative Analysis of Variant Reporting and HRD Performance: Evaluating AVENIO Tumor Tissue CGP Automated Assay Against F1CDx Assay and PGDx elio Test (AMP 2024)
    The AVENIO CGP Assay demonstrated high agreement with 2 established CGP tests, F1CDx and PGDx, in variant reporting, and closely aligned with F1CDx in HRDsig analysis across various tissue types. These results highlight the assay's reliability and demonstrate its utility in translational research.
    Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRD (Homologous Recombination Deficiency)
    |
    HER-2 amplification • HRD • ALK rearrangement • RET rearrangement • HRD signature
    |
    FoundationOne® CDx • AVENIO Tumor Tissue CGP Kit • PGDx elio™ tissue complete assay
    2d
    Analytical Performance of the New Illumina TruSight Oncology 500 V2 Assay for Comprehensive Genomic Profiling (AMP 2024)
    The new Illumina TSO500 v2 assay features a simplified workflow with improved performance and reduced turnaround time. Driven by innovations in assay design and bioinformatics, these capabilities can accelerate the democratization of actionable cancer biomarker detection, from small variants and copy number variants to RNA variants and complex biomarker outputs like TMB, MSI, and GIS scores.
    Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    TruSight Oncology 500 Assay
    2d
    Analytical Validation of the Promega Long Mononucleotide Repeat Microsatellite Instability Assay (AMP 2024)
    Via the analysis of longer homopolymer repeat regions, the Promega LMR MSI assay demonstrates enhanced sensitivity for subtle phenotypes. This assay may be better suited than other PCR- and CE-based approaches for certain disease types.
    Microsatellite instability • MSi-H Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Idylla™ MSI Test
    2d
    Clinical Validation of an In-House-Developed Somatic Copy Number Calling Pipeline to Use on the TruSight Oncology 500 Next-Generation Sequencing (TSO500) Kit in Solid Tumors (AMP 2024)
    The OncCNV pipeline accurately detects GAMP, HMZ, and BI beyond the reportable range validated by Illumina. Development of the OncCNV pipeline further enhances the clinical utility of the TSO500 assay, as demonstrated in this cohort of solid tumor samples.
    Clinical • Next-generation sequencing • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TruSight Oncology 500 Assay
    2d
    Comprehensive Evaluation of Copy Number Variation from Gene to Arm-Level Using Targeted Sequencing (AMP 2024)
    OCA Plus supports comprehensive detection of relevant copy number alterations in cancer FFPE samples. Combined with small variant profiling, detection of MSI, TMB, and HRD, OCA Plus facilitates comprehensive analysis of DNA structural changes in cancer that are relevant to precision oncology research.
    Tumor mutational burden • BRCA Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • HRD (Homologous Recombination Deficiency)
    |
    IDH1 mutation • HRD • IDH1 mutation + Chr del(1p) + Chr del(19q)
    |
    Oncomine™ Comprehensive Assay Plus
    2d
    Performance of Idylla MSI and Promega LMR Assays for Pan-Cancer Testing of Microsatellite Instability at Temple University Health System (AMP 2024)
    Both assays showed comparable sensitivity in establishing MSI status for CRC and the expanded spectrum of non-CRC tumors. Advantages such as increased number of LMR loci in the Promega assay and the need for only tumor specimen in the Idylla assay increase the utility of these assays in determination of MSI status in a variety of cancers.
    Microsatellite instability • MSi-H Biomarker • Pan tumor
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Idylla™ MSI Test
    2d
    Automation of the New Illumina TruSight Oncology 500 v2 Assay on the Beckman Coulter Biomek i7 Workstation (AMP 2024)
    The new TSO500 v2 assay with automated library prep on the Biomek i7 workstation was demonstrated to perform comparably to manual library prep and offers a high-throughput solution to enable comprehensive genomic profiling with a faster, more flexible workflow and easier-to-use reagent kit.
    Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    TruSight Oncology 500 Assay
    2d
    Evaluation of Promega OncoMate MSI Dx Analysis System in Colorectal Cancer, Endometrial Cancer, and Sebaceous Neoplasms (AMP 2024)
    The research study demonstrated the effectiveness of the Promega OncoMate MSI Dx Analysis System in detecting MSI in colorectal cancer, endometrial cancer, and sebaceous neoplasms in comparison with MMR IHC. The correlation for CRC was excellent, and EC and SN showed good correlation, though further investigation into discordant samples is necessary. This research study indicates that the OncoMate MSI Dx test offers excellent clinical utility in the diagnosis and management of LS in CRC, and can provide additional insights into EC and SN sample MSI status for LS and MTS research.
    MSi-H Biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    OncoMate™ MSI
    2d
    A Pilot Evaluation of the Workflow and Performance Characteristics of the Illumina TruSight Oncology 500 ctDNA v2 Assay (AMP 2024)
    In this pilot study, the TSO500 ctDNA v2 provided workflow enhancements with decreased overall turnaround time compared to TSO500 ctDNA v1, as well as low DNA input requirement, excellent sensitivity, and high accuracy.
    Tumor mutational burden • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TruSight Oncology 500 Assay • TruSight Oncology 500 ctDNA v2
    2d
    Automation of the New Illumina TruSight Oncology 500 v2 Assay on the Hamilton Microlab NGS STAR MOA System (AMP 2024)
    The new TSO500 v2 assay with automated library prep on the NGS STAR MOA liquid handler was demonstrated to perform comparably to manual library prep and offers a high-throughput solution to enable comprehensive genomic profiling with a faster, more flexible workflow and easier-to-use reagent kit.
    Next-generation sequencing • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    TruSight Oncology 500 Assay
    2d
    Frequency of FDA-Approved Companion Diagnostic Biomarkers in Solid Tumors (AMP 2024)
    Genomic profiling yields clinically actionable information for approved therapies and evidence of resistance, and it may uncover rational therapeutic opportunities regardless of tumor type.
    Tumor mutational burden • Companion diagnostic • BRCA Biomarker • MSi-H Biomarker • BRCA Companion diagnostic • MSi-H Companion diagnostic
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    BRAF V600E • KRAS mutation • BRCA2 mutation • TMB-H • MSI-H/dMMR • KRAS G12C • HER-2 negative • PIK3CA mutation • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • RET fusion • ROS1 fusion • KRAS G12 • KRAS exon 2 mutation • ALK-ROS1 fusion
    |
    OncoExTra™ test
    2d
    Simplifying the AVENIO Tumor Tissue CGP Manual Workflow: Performance of HRD, TMB, and MSI Signature Detection (AMP 2024)
    As evidence for multi-biomarker and complex genomic signatures grows in precision oncology, molecular pathology labs must evolve their sequencing capabilities with the latest innovation. The new AVENIO Tumor Tissue CGP Kit V2 demonstrates high performance and incorporates faster workflows, higher throughput, improved bioinformatics algorithms, and successful incorporation of a new HRD signature.
    Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    HRD • HRD signature • High HRD score
    |
    AVENIO Tumor Tissue CGP Kit
    2d
    Reporting the Discrete Data of Four NGS Panels into the EHR System: A Single-Institute Experience (AMP 2024)
    Since its initial proposal in December of 2022, discrete reporting at the University of California, San Diego genomic lab was an effort that took close to a year-and-a-half to accomplish. Although the process was not without its hardships, the decision to go with an in-house approach saved the lab both time and resources compared to an outside approach. By exploring the capabilities and functionalities of its current laboratory information systems and EHR systems, the lab built a discrete reporting system that is effective for its needs as well as a framework for converting other and future NGS assays to discrete reporting.
    Next-generation sequencing • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TruSight Oncology 500 Assay • Oncomine Precision Assay
    2d
    Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers (clinicaltrials.gov)
    P2, N=35, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    2d
    SEAMARK: A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=101, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib)
    3d
    Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting | N=31 --> 62 | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition • Mismatch repair • Surgery • Checkpoint block • Metastases
    |
    MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR • POLE mutation
    |
    Jemperli (dostarlimab-gxly)
    3d
    Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=12 --> 19
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)
    3d
    Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Trodelvy (sacituzumab govitecan-hziy)
    3d
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    NOUS-209
    5d
    A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (ChiCTR2400089007)
    P2, N=130, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
    New P2 trial • Combination therapy
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    MSI-H/dMMR • BRCA mutation • MSH6 expression
    |
    FoundationOne® CDx
    |
    5-fluorouracil • sacituzumab tirumotecan (MK-2870)
    5d
    Phase I/ II clinical study of TAS-102 in combination with Fruquintinib and Sintilimab treat in patients with micro-satellite stable metastatic Colorectal cancer who have failed standard therapy (ChiCTR2400089944)
    P1/2, N=62, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    5d
    Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer (ChiCTR2400089659)
    P1, N=30, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P1 trial • Combination therapy • Metastases
    |
    MSI (Microsatellite instability) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    capecitabine
    7d
    Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    8d
    A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=295, Recruiting, Hoffmann-La Roche | N=220 --> 295
    Enrollment change • Combination therapy • Mismatch repair • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    8d
    NEK2 is a potential pan-cancer biomarker and immunotherapy target. (PubMed, Discov Oncol)
    NEK2 may be a potential pan-cancer biomarker and immunotherapeutic target for improving the efficacy of tumor therapy.
    Journal • Tumor mutational burden • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NEK2 (NIMA Related Kinase 2)
    9d
    High risk of multiple gastric cancers in Japanese individuals with Lynch syndrome. (PubMed, Ann Gastroenterol Surg)
    Notably, the cumulative risk of individuals with LS developing metachronous and/or synchronous GCs at 0, 10 and 20 y after initial diagnosis of GC was 26.7%, 40.7%, and 59.4%, respectively. Due to a higher risk of developing multiple GCs, intensive surveillance might be especially recommended for Japanese individuals with LS associated initial GC.
    Journal
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    9d
    LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845
    9d
    SGSM2 in Uveal Melanoma: Implications for Survival, Immune Infiltration, and Drug Sensitivity. (PubMed, Protein Pept Lett)
    SGSM2 may not only serve as an important indicator for prognostic assessment. Still, it may also be a key target for the development of new therapeutic approaches, providing new perspectives on the treatment of UVM patients.
    Journal
    |
    MSI (Microsatellite instability)
    |
    GSK690693 • PHA 793887
    9d
    Potential microbial effects on microsatellite instability possibly drive divergence in colorectal cancer immunotherapy responses among different anatomical subsites. (PubMed, Gut)
    No abstract available
    Journal • Microsatellite instability
    |
    MSI (Microsatellite instability)
    9d
    Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study. (PubMed, J Immunother Cancer)
    CD47 expression in CRC was associated with the activation of several oncogenic pathways and an immune-engaged TME. Our findings may provide valuable information for considering new therapeutic strategies targeting innate immune checkpoints in CRC.
    Journal • MSi-H Biomarker • IO biomarker
    |
    MSI (Microsatellite instability) • CD47 (CD47 Molecule)
    |
    MSI-H/dMMR • CD47 expression
    9d
    KRAS mutations in endometrial cancers: Possible prognostic and treatment implications. (PubMed, Gynecol Oncol)
    KRAS-mut represents a genotypically distinct group of ECs. Overlap exists with genomic predictors (TMB-high, MSI-high) of immunotherapy response, suggesting a possible biomarker-driven combination option with immunotherapy. Clinical trials to evaluate these strategies should be developed.
    Journal • Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability)
    |
    KRAS mutation • BRCA2 mutation • BRCA1 mutation • TMB-H • MSI-H/dMMR • HER-2 overexpression • KRAS G12D • KRAS G12V • KRAS wild-type • KRAS overexpression • HER-2 positive + RAS wild-type
    11d
    Comprehensive Analysis and Experimental Validation of HEPACAM2 as a Potential Prognosis Biomarker and Immunotherapy Target in Colorectal Cancer. (PubMed, Curr Gene Ther)
    These findings suggest that HEPACAM2 may serve as a potential prognostic biomarker and immunotherapeutic target for CRC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    EPCAM expression
    11d
    A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Inspirna, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • ompenaclid (RGX-202)
    11d
    DESTINY-CRC02: Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=122, Completed, Daiichi Sankyo | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2024
    Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    11d
    T2WI and ADC radiomics combined with a nomogram based on clinicopathologic features to quantitatively predict microsatellite instability in colorectal cancer. (PubMed, Acad Radiol)
    A radiomics nomogram based on T2WI and ADC sequences and clinicopathologic features can effectively and noninvasively predict the MSI status in CRC. This approach helps clinicians in stratifying CRC patients and making clinical decisions for personalized treatment.
    Journal • Microsatellite instability
    |
    MSI (Microsatellite instability) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    14d
    Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines. (PubMed, Cancer Res Commun)
    We found that in cell lines, HRD was associated with sensitivity to PARP inhibition in breast cancer, but not at a pan-cancer level. By generating large-scale, pan-cancer datasets on HRD predictions in cell lines, we aim to facilitate efforts to improve our understanding of HRD and its utility as a biomarker.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation
    14d
    Spatial context of immune checkpoints as predictors of overall survival in patients with resectable colorectal cancer independent of standard TNM stages. (PubMed, Cancer Res Commun)
    We found that the spatial context of PD-1 and TIM-3 successfully predicted the overall survival of CRC patients independent of TNM stage. Dual targeting of PD-1 and TIM-3 in mouse tumor models inhibited tumor progression and reduced T-cell exhaustion, indicating a potential strategy for improving the clinical treatment of CRC.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    MSI-H/dMMR • PD-1 expression • HAVCR2 expression
    14d
    Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing. (PubMed, bioRxiv)
    In the equal access VA healthcare setting, Veterans undergoing NGS for mPCa exhibited differences in alteration frequencies in both actionable and non-actionable pathways that may be associated with survival. This analysis affirms the utility of genomic testing for identifying candidates irrespective of race/ethnicity for precision oncology treatments, which could contribute to equitable outcomes in patients with mPCa.
    Journal • Next-generation sequencing • MSi-H Biomarker • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • SPOP (Speckle Type BTB/POZ Protein)
    |
    MSI-H/dMMR
    14d
    MT-8421-001: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types (clinicaltrials.gov)
    P1, N=15, Terminated, Molecular Templates, Inc. | Active, not recruiting --> Terminated; Sponsor Termination
    Trial termination
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • MT-8421
    14d
    XTX301-01: XTX301 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, Xilio Development, Inc. | Phase classification: P1 --> P1/2 | N=174 --> 358
    Phase classification • Enrollment change • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    XTX301